2Q EARNINGS: Biogen revenue surprises, stock rises; Plegridy approved in EU
This article was originally published in Scrip
Executive Summary
Biogen Idec surprised investors with a 40% year-over-year increase in second quarter revenue driven by the oral multiple sclerosis drug Tecfidera (dimethyl fumarate), but the company got a surprise of its own on 23 July – approval in the EU for Plegridy, a pegylated interferon beta-1a for relapsing-remitting MS that's injected every two weeks.